Quantifying Differences in Hepatic Uptake of the Liver Specific Contrast Agents Gd-EOB-DTPA and Gd-BOPTA: a Pilot Study
Overview
Affiliations
Objectives: To develop and evaluate a procedure for quantifying the hepatocyte-specific uptake of Gd-BOPTA and Gd-EOB-DTPA using dynamic contrast-enhanced (DCE) MRI.
Methods: Ten healthy volunteers were prospectively recruited and 21 patients with suspected hepatobiliary disease were retrospectively evaluated. All subjects were examined with DCE-MRI using 0.025 mmol/kg of Gd-EOB-DTPA. The healthy volunteers underwent an additional examination using 0.05 mmol/kg of Gd-BOPTA. The signal intensities (SI) of liver and spleen parenchyma were obtained from unenhanced and enhanced acquisitions. Using pharmacokinetic models of the liver and spleen, and an SI rescaling procedure, a hepatic uptake rate, K (Hep), estimate was derived. The K (Hep) values for Gd-EOB-DTPA were then studied in relation to those for Gd-BOPTA and to a clinical classification of the patient's hepatobiliary dysfunction.
Results: K (Hep) estimated using Gd-EOB-DTPA showed a significant Pearson correlation with K (Hep) estimated using Gd-BOPTA (r = 0.64; P < 0.05) in healthy subjects. Patients with impaired hepatobiliary function had significantly lower K (Hep) than patients with normal hepatobiliary function (K (Hep) = 0.09 ± 0.05 min(-1) versus K (Hep) = 0.24 ± 0.10 min(-1); P < 0.01).
Conclusions: A new procedure for quantifying the hepatocyte-specific uptake of T (1)-enhancing contrast agent was demonstrated and used to show that impaired hepatobiliary function severely influences the hepatic uptake of Gd-EOB-DTPA.
Key Points: • The liver uptake of contrast agents may be measured with standard clinical MRI. • Calculation of liver contrast agent uptake is improved by considering splenic uptake. • Liver function affects the uptake of the liver-specific contrast agent Gd-EOB-DTPA. • Hepatic uptake of two contrast agents (Gd-EOB-DTPA, Gd-BOPTA) is correlated in healthy individuals. • This method can be useful for determining liver function, e.g. before hepatic surgery.
Gunwhy E, Hines C, Green C, Laitinen I, Tadimalla S, Hockings P MAGMA. 2024; 37(4):697-708.
PMID: 39105950 PMC: 11417070. DOI: 10.1007/s10334-024-01192-5.
Liver metastases: The role of magnetic resonance imaging.
Maino C, Vernuccio F, Cannella R, Cortese F, Franco P, Gaetani C World J Gastroenterol. 2023; 29(36):5180-5197.
PMID: 37901445 PMC: 10600959. DOI: 10.3748/wjg.v29.i36.5180.
Karlsson M, Simonsson C, Dahlstrom N, Cedersund G, Lundberg P PLoS One. 2023; 18(1):e0279168.
PMID: 36608050 PMC: 9821424. DOI: 10.1371/journal.pone.0279168.
Mori H, Akimoto S Quant Imaging Med Surg. 2022; 12(12):5343-5357.
PMID: 36465824 PMC: 9703119. DOI: 10.21037/qims-22-174.
Li X, Huang R, Yang M, Wang J, Gao Y, Jin Q World J Gastroenterol. 2022; 28(20):2214-2226.
PMID: 35721884 PMC: 9157620. DOI: 10.3748/wjg.v28.i20.2214.